BetterLife Pharma Inc. (OTCMKTS:BETRF) Sees Large Decline in Short Interest

BetterLife Pharma Inc. (OTCMKTS:BETRF) saw a large decrease in short interest in the month of September. As of September 30th, there was short interest totaling 70,369 shares, a decrease of 44.5% from the September 15th total of 126,688 shares. Approximately 0.1% of the shares of the stock are sold short. Based on an average daily volume of 248,857 shares, the days-to-cover ratio is presently 0.3 days.

BetterLife Pharma Trading Up 3.2%

Shares of BETRF stock opened at $0.16 on Friday. BetterLife Pharma has a 12-month low of $0.03 and a 12-month high of $0.33. The business’s 50 day moving average is $0.22 and its two-hundred day moving average is $0.13. The company has a market capitalization of $27.64 million, a P/E ratio of -16.25 and a beta of 0.21.

BetterLife Pharma (OTCMKTS:BETRF) last posted its quarterly earnings data on Tuesday, September 29th. The company reported ($0.01) EPS for the quarter.

BetterLife Pharma Company Profile

BetterLife Pharma Inc is a Canadian biotechnology company focused on developing innovative therapies for mental health and neurological disorders. The company’s research platform is based primarily on psychedelic-derived compounds designed to provide therapeutic benefits while reducing or eliminating unwanted hallucinogenic effects.

Its lead development program centers on BETR-001, a proprietary formulation of 2-bromo-LSD, which BetterLife is evaluating as a potential treatment for depression and related mental health conditions.